Related references
Note: Only part of the references are listed.The use of Zymosan A and bacteria anchored to tumor cells for effective cancer immunotherapy: B16-F10 murine melanoma model
Eva Waldmannova et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2016)
Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells
Moonkyu Lee et al.
ARCHIVES OF PHARMACAL RESEARCH (2014)
The Use of Anchored Agonists of Phagocytic Receptors for Cancer Immunotherapy: B16-F10 Murine Melanoma Model
Tereza Janotova et al.
PLOS ONE (2014)
The design and proof of concept for a CD8+ T cell-based vaccine inducing cross-subtype protection against influenza A virus
Amabel C. L. Tan et al.
IMMUNOLOGY AND CELL BIOLOGY (2013)
Anticancer TLR agonists on the ropes
Malini Guha
NATURE REVIEWS DRUG DISCOVERY (2012)
Systemic Cancer Therapy with a Small Molecule Agonist of Toll-like Receptor 7 Can Be Improved by Circumventing TLR Tolerance
Carole Bourquin et al.
CANCER RESEARCH (2011)
Immunotherapeutic modulation of the suppressive liver and tumor microenvironments
Tim Chan et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2011)
Septic Shock Is Associated with Receptor for Advanced Glycation End Products Ligation of LPS
Yasuhiko Yamamoto et al.
JOURNAL OF IMMUNOLOGY (2011)
Resilience to Bacterial Infection: Difference between Species Could Be Due to Proteins in Serum
H. Shaw Warren et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Neutrophil function in inflammation and inflammatory diseases
Helen L. Wright et al.
RHEUMATOLOGY (2010)
Silencing of signal transducer and activator of transcription 3 expression by RNA interference suppresses growth of human hepatocellular carcinoma in tumor-bearing nude mice
Jing Li et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2009)
Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function
Ian S. Zagon et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2008)
Immunization with a toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice
Wen-Wei Zhang et al.
INFECTION AND IMMUNITY (2008)
TLR7 and TLR8 as targets in cancer therapy
M. P. Schoen et al.
ONCOGENE (2008)
The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy
Evelien L. J. M. Smits et al.
ONCOLOGIST (2008)
Macrophage tolerance induced by stimulation with Toll-like receptor 7/8 ligands
Kunihisa Tsukada et al.
IMMUNOLOGY LETTERS (2007)
The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4
Veronica Mata-Haro et al.
SCIENCE (2007)
Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists
Holger Kanzler et al.
NATURE MEDICINE (2007)
Cooperation of Toll-like receptor signals in innate immune defence
Giorgio Trinchieri et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Maturation of murine bone marrow-derived dendritic cells with poly(I:C) produces altered TLR-9 expression and response to CpG DNA
Hironori Tsujimoto et al.
IMMUNOLOGY LETTERS (2006)
A novel glyco-conjugate vaccine against fungal pathogens
A Torosantucci et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Rapid protein anchoring into the membranes of mammalian cells using oleyl chain and poly(ethylene glycol) derivatives
K Kato et al.
BIOTECHNOLOGY PROGRESS (2004)
TNF-α induces phosphorylation of p47phox in human neutrophils:: Partial phosphorylation of p47phox is a common event of priming of human neutrophils by TNF-α and granulocyte-macrophage colony-stimulating factor
C Dewas et al.
JOURNAL OF IMMUNOLOGY (2003)
Toll-like receptors stimulate human neutrophil function
F Hayashi et al.
BLOOD (2003)
A variety of microbial components induce tolerance to lipopolysaccharide by differentially affecting MyD88-dependent and -independent pathways
S Sato et al.
INTERNATIONAL IMMUNOLOGY (2002)
Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod
SJ Gibson et al.
CELLULAR IMMUNOLOGY (2002)
Mixture of trypsin, chymotrypsin and papain reduces formation of metastases and extends survival time of C57Bl6 mice with syngeneic melanoma B16
M Wald et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2001)
The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes
MA Tomai et al.
CELLULAR IMMUNOLOGY (2000)
Share Paper
